A business in context
GILD research notebook
Read the disclosures. Follow the relationships. Keep the dates in view.
Filing timeline
Download filings CSVReported insider transactions
Download transactions CSVP · PurchaseS · SaleA · Grant / awardM · Exercise / conversionF · Tax / exercise paymentG · Gift
| Transaction / filed | Reporting owner | Type | Security | Shares | Reported price |
|---|---|---|---|---|---|
| 2026-06-15 | Mercier Johanna | S · Sale | Common Stock | 1480.0 | 123.42 |
| 2026-06-15 | Mercier Johanna | S · Sale | Common Stock | 450.0 | 125.4 |
| 2026-06-15 | Mercier Johanna | S · Sale | Common Stock | 1070.0 | 124.0 |
| 2026-06-15 | Dickinson Andrew D | S · Sale | Common Stock | 3000.0 | 125.4 |
| 2026-06-10 | Cain Wettan Keeley M | F · Tax / exercise payment | Common Stock | 283.0 | 121.48 |
| 2026-06-10 | Cain Wettan Keeley M | M · Exercise / conversion | Common Stock | 589.0 | — |
| 2026-06-10 | Cain Wettan Keeley M | M · Exercise / conversion | Restricted Stock Unit | 589.0 | — |
| 2026-06-10 | Mercier Johanna | F · Tax / exercise payment | Common Stock | 1341.0 | 121.48 |
| 2026-06-10 | Mercier Johanna | M · Exercise / conversion | Common Stock | 2796.0 | — |
| 2026-06-10 | Mercier Johanna | M · Exercise / conversion | Restricted Stock Unit | 2796.0 | — |
| 2026-06-10 | Berger Dietmar | F · Tax / exercise payment | Common Stock | 263.0 | 121.48 |
| 2026-06-10 | Berger Dietmar | M · Exercise / conversion | Common Stock | 533.0 | — |
| 2026-06-10 | Berger Dietmar | M · Exercise / conversion | Restricted Stock Unit | 533.0 | — |
| 2026-06-10 | O'Day Daniel Patrick | F · Tax / exercise payment | Common Stock | 4213.0 | 121.48 |
| 2026-06-10 | O'Day Daniel Patrick | M · Exercise / conversion | Common Stock | 8779.0 | — |
| 2026-06-10 | O'Day Daniel Patrick | M · Exercise / conversion | Restricted Stock Unit | 8779.0 | — |
| 2026-06-10 | Dickinson Andrew D | F · Tax / exercise payment | Common Stock | 1341.0 | 121.48 |
| 2026-06-10 | Dickinson Andrew D | M · Exercise / conversion | Common Stock | 2796.0 | — |
| 2026-06-10 | Dickinson Andrew D | M · Exercise / conversion | Restricted Stock Unit | 2796.0 | — |
| 2026-06-01 | O'Day Daniel Patrick | S · Sale | Common Stock | 10900.0 | 131.1 |
| 2026-06-01 | O'Day Daniel Patrick | S · Sale | Common Stock | 3062.0 | 132.22 |
| 2026-06-01 | O'Day Daniel Patrick | S · Sale | Common Stock | 1038.0 | 132.97 |
| 2026-05-15 | Mercier Johanna | S · Sale | Common Stock | 700.0 | 132.75 |
| 2026-05-15 | Mercier Johanna | S · Sale | Common Stock | 11177.0 | 131.19 |
| 2026-05-15 | Mercier Johanna | S · Sale | Common Stock | 8374.0 | 132.23 |
| 2026-05-15 | Mercier Johanna | M · Exercise / conversion | Common Stock | 25000.0 | 66.64 |
| 2026-05-15 | Mercier Johanna | S · Sale | Common Stock | 7749.0 | 130.29 |
| 2026-05-15 | Mercier Johanna | M · Exercise / conversion | Non-qualified Stock Option (Right to Buy) | 25000.0 | 0.0 |
| 2026-05-15 | Dickinson Andrew D | S · Sale | Common Stock | 3000.0 | 132.27 |
| 2026-04-30 | Horning Sandra | A · Grant / award | Common Stock | 1146.0 | 0.0 |
| 2026-04-30 | Horning Sandra | A · Grant / award | Non-qualified Stock Option (Right to Buy) | 4884.0 | 0.0 |
| 2026-04-30 | Kramer Kelly A. | A · Grant / award | Non-qualified Stock Option (Right to Buy) | 4884.0 | 0.0 |
| 2026-04-30 | Kramer Kelly A. | A · Grant / award | Restricted Stock Unit | 1146.0 | 0.0 |
| 2026-04-30 | MANWANI HARISH | A · Grant / award | Common Stock | 1146.0 | 0.0 |
| 2026-04-30 | MANWANI HARISH | F · Tax / exercise payment | Common Stock | 224.0 | 130.84 |
| 2026-04-30 | MANWANI HARISH | A · Grant / award | Non-qualified Stock Option (Right to Buy) | 4884.0 | 0.0 |
| 2026-04-30 | Rodriguez Javier | A · Grant / award | Common Stock | 1146.0 | 0.0 |
| 2026-04-30 | Rodriguez Javier | A · Grant / award | Non-qualified Stock Option (Right to Buy) | 4884.0 | 0.0 |
| 2026-04-30 | WELTERS ANTHONY | A · Grant / award | Common Stock | 1146.0 | 0.0 |
| 2026-04-30 | WELTERS ANTHONY | A · Grant / award | Non-qualified Stock Option (Right to Buy) | 4884.0 | 0.0 |
| 2026-04-30 | LOVE TED W | A · Grant / award | Common Stock | 1146.0 | 0.0 |
| 2026-04-30 | LOVE TED W | A · Grant / award | Non-qualified Stock Option (Right to Buy) | 4884.0 | 0.0 |
| 2026-04-30 | BARTON JACQUELINE K | A · Grant / award | Common Stock | 1146.0 | 0.0 |
| 2026-04-30 | BARTON JACQUELINE K | A · Grant / award | Non-qualified Stock Option (Right to Buy) | 4884.0 | 0.0 |
| 2026-04-30 | Bluestone Jeffrey | A · Grant / award | Common Stock | 1146.0 | 0.0 |
| 2026-04-30 | Bluestone Jeffrey | A · Grant / award | Non-qualified Stock Option (Right to Buy) | 4884.0 | 0.0 |
| 2026-04-28 | O'Day Daniel Patrick | S · Sale | Common Stock | 3050.0 | 130.01 |
| 2026-04-28 | O'Day Daniel Patrick | S · Sale | Common Stock | 6950.0 | 128.79 |
| 2026-04-15 | Mercier Johanna | S · Sale | Common Stock | 3000.0 | 140.96 |
| 2026-04-15 | Dickinson Andrew D | S · Sale | Common Stock | 3000.0 | 140.96 |
Identity & relationships
SEC issuer · 0000882095GILEAD SCIENCES, INC.
Gilead Sciences LtdGilead Sciences (Australia)Kite Pharma
- Legal Entity Identifier
- 549300WTZWR07K8MNV44
- GLEIF legal name
- GILEAD SCIENCES, INC.
- Entity / LEI registration status
- ACTIVE / ISSUED
- Reference data updated
- 2026-03-03T10:10:30Z
Search names and former names
View Wikidata identity and references ↗
- Gilead Sciences · alias · wikidata
- Gilead · alias · wikidata
- Gilead Sciences Ltd · subsidiary · wikidata
- NEXSTAR PHARMACEUTICALS LIMITED · subsidiary · wikidata
- VESTAR LIMITED · subsidiary · wikidata
- MAPLESTORE LIMITED · subsidiary · wikidata
- Gilead Sciences (Australia) · subsidiary · wikidata
- Kite Pharma · subsidiary · wikidata
- Kite Pharma Inc · subsidiary · wikidata
- GILEAD SCIENCES INC · former SEC name · 1994-02-14 to 2022-02-17
Revenue in constant purchasing power
| Year ended | Reported USD revenue | CPI-adjusted USD revenue |
|---|---|---|
| 2024-12-31 | $28.75B | $30.61B |
| 2023-12-31 | $27.12B | $29.71B |
| 2022-12-31 | $27.28B | $31.12B |
| 2021-12-31 | $27.30B | $33.64B |
| 2020-12-31 | $24.69B | $31.85B |
| 2019-12-31 | $22.45B | $29.32B |
| 2018-12-31 | $22.13B | $29.42B |
| 2017-12-31 | $26.11B | $35.56B |